February 7, 2025 03:45 AM EST

Roche heads to FDA with Gazyva results in a form of lupus

Lei Lei Wu

News Reporter

Almost 16 years after Rituxan’s disappointing data in lupus, Roche’s Genentech found success with a different B cell-killing drug called Gazyva in lupus nephritis …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Roche heads to FDA with Gazyva results in a form of lupus

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Less than two years after blockbuster IPO, Acelyrin merges with Alumis to combine cash, assets

Bristol Myers prunes pipeline amid new round of cost cuts

Pfizer hires Novartis oncology exec to steer its cancer ambitions

AstraZeneca takes $753M charge on abandoned complement drug from Alexion deal

Bristol Myers launches fresh round of major cost cuts in bid to get ahead of patent cliff

Updated: Lilly posts 45% sales jump, culls four programs across obesity, Alzheimer's, heart failure and eczema

Roche heads to FDA with Gazy­va re­sults in a form of lu­pus

News Reporter

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

Roche heads to FDA with Gazyva results in a form of lupus